The SORAYA study (NCT04296890), a single-arm phase III trial, evaluated mirvetuximab in patients with platinum-resistant ovarian cancer and high FRα expression (≥75% of strongly expressed, 2+/3+ cancer cells) [66]. This evidence concerns the gene FOLR1 and ovarian carcinoma.